Morgan Stanley assumed coverage of BeiGene (BGNE) with an Overweight rating and $300 price target The firm sees BeiGene’s Brukinsa continuing to gain share within the Bruton Tyrosine Kinase inhibitors market and notes that the company also has two complementary drug candidates entering Phase 3 clinical trials in the first half of 2025, which it says will enhance the company’s “leading position” in the treatment of B-cell malignancies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: